Song, H.J., Seo, H.J., & Son, H. (2016). Comparative effectiveness of ramosetron for preventing chemotherapy-induced nausea and vomiting: A systematic review and meta-analysis. European Journal of Clinical Pharmacology, 72, 1289–1301.
STUDY PURPOSE: To evaluate the effectiveness and safety of ramosetron for chemotherapy-induced nausea and vomiting (CINV) through a systematic review of randomized, controlled trials (RCTs)
TYPE OF STUDY: Meta-analysis and systematic review
PHASE OF CARE: Active antitumor treatment
In the acute phase, ramosetron significantly reduced nausea and acute vomiting compared to other 5HT3RAs. In the delayed phase, difference in complete response of nausea existed between ramosetron and other 5-HT3RAs. No significant differences existed between common adverse reactions.
The study concluded that ramosetron for CINV may be as effective and as tolerable as other 5-HT3RAs, but more well-designed RCTs are needed to confirm the effect of ramosetron on acute or delayed CINV in patients with cancer.
The methodological quality of studies was not high (different dosages, missing data, limited information on MEC or low risk).
Ramosetron may be effective for CINV and as tolerable as other 5HT3RAs. More well-designed RCTs are needed to confirm the effect of ramosetron on acute or delayed CINV.